Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), a first-in-class candidate for multiple sclerosis (MS). This clearance allows the company to proceed with a Phase 2 clinical trial, a critical milestone in the development of a therapy that could alter the course of the disease.
The upcoming Phase 2 study is designed as a randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS. Clinical and radiological measures will be used to assess outcomes. The company has already initiated trial start-up activities, including site selection, with patient enrollment and drug administration expected to begin as soon as possible.
Lucid-MS is distinguished from existing MS therapies by its neuroprotective mechanism. While current treatments primarily modulate the immune system, Lucid-MS targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. By inhibiting PAD2, Lucid-MS aims to prevent and potentially reverse myelin breakdown, a key pathological feature of MS. Preclinical models have demonstrated its ability to prevent and reverse demyelination, and prior Phase 1 trials showed a favorable safety profile and tolerability in healthy participants.
The significance of this FDA clearance cannot be overstated. MS affects millions worldwide, and current disease-modifying therapies often have limited efficacy in progressive forms of the disease and are associated with significant side effects. A therapy that directly protects myelin could offer a new avenue for treatment, potentially slowing or halting disability progression.
Quantum BioPharma's financial position, with over $10 million in cash, digital assets, and liquid investments as of March 31, 2026, suggests it has the resources to advance the trial. However, the path to market is still long, with Phase 2 results expected to provide crucial data on efficacy and safety.
The company is also advancing other assets, including UNBUZZD, a product for alcohol misuse, but Lucid-MS remains its lead candidate. This regulatory milestone could enhance investor confidence and position Quantum BioPharma as a key player in the neurodegenerative disease space.
For more details on the press release, visit https://ibn.fm/HyWYH. To stay updated on Quantum BioPharma's latest news, visit their newsroom at https://ibn.fm/QNTM.
